Over 2 million cases of Bloodstream Infection (BSI) occur in North America and Europe each year, associated with 250,000 patients’ death. Of note, the mortality rate of BSI increases by 8% for each hour the antibiotic treatment is delayed, and those patients who receive the wrong antibiotic over this period, face a ten-fold increase in mortality. Also, rapid analyzing blood samples for bacterial resistance is also a critical step in reducing the mortality risk posed by a BSI. On the other hand, established clinical bioassays to isolate and detect bacteria and perform antibiotic susceptibility testing (AST) are cost-intensive, tedious, need a large amount of sample volume (10–30 mL), and are time-consuming, typically requiring 3-5 days. We developed an EasyOmics Plate coupled with mass spectrometry for rapid antibiotic susceptibility testing to address this challenge. An EasOmics plate is an integral part of the workflow, allowing for the incubation and sampling of the patient samples in one step.